| Univariate | Multivariate | ||||
---|---|---|---|---|---|---|
 | OR | 95% CI | p value | OR | 95% CI | p value |
Male | 1.09 | 0.39–3.30 | 1.00 |  |  |  |
Age (1Â year increase) | 1.008 | 098-1.04 | 0.65 | Â | Â | Â |
BMI | 1.04 | 0.96–1.12 | 0.35 |  |  |  |
Hypertension | 1.12 | 0.37–3.38 | 1.00 |  |  |  |
Dyslipidemia | 2.01 | 0.82–5.14 | 0.14 |  |  |  |
Aspirin* | – | – | – |  |  |  |
Clopidogrel* | 1.01 | 0.51–2.02 | 1.00 |  |  |  |
Prasugrel* | 1.15 | 0.58–2.32 | 0.72 |  |  |  |
Ticlopidine* | 0.42 | 0.048–3.71 | 0.38 |  |  |  |
Statin* | 2.11 | 0.94–4.72 | 0.088 | 2.44 | 1.01–5.87 | 0.047 |
Insulin, n (%) | 0.82 | 0.32–2.11 | 0.82 |  |  |  |
Biguanide, n (%) | 1.43 | 0.68–3.03 | 0.44 |  |  |  |
DPP-4 inhibitor, n (%) | 1.36 | 0.68–2.74 | 0.48 |  |  |  |
SGLT-2 inhibitor, n (%) | 0.53 | 0.058-4.90 | 0.50 | Â | Â | Â |
Thiazolidine, n (%) | 0.82 | 0.27–2.44 | 0.79 |  |  |  |
Sulfonylurea, n (%) | 2.62 | 1.23–5.57 | 0.016 | 3.87 | 1.66–9.01 | 0.002 |
Glinide, n (%) | 0.93 | 0.23–3.75 | 0.61 |  |  |  |
α-glucosidase inhibitor, n (%) | 1.78 | 0.79–4.04 | 0.19 |  |  |  |
Follow-up duration (1 day increase) | 0.995 | 0.984–1.007 | 0.44 |  |  |  |
ACS | 1.13 | 0.53–2.37 | 0.85 |  |  |  |
Pre-dilatation balloon maximum diameter (1 mm increase) | 1.09 | 0.63–1.90 | 0.76 |  |  |  |
Pre-dilatation balloon maximum inflation pressure (1 atm increase) | 1.06 | 0.96–1.16 | 0.28 |  |  |  |
Maximum stent diameter (1 mm increase) | 1.49 | 0.69–3.20 | 0.31 |  |  |  |
Minimum stent diameter (1 mm increase) | 1.13 | 0.50–2.53 | 0.77 |  |  |  |
Stent implantation pressure (1 atm increase) | 0.91 | 0.81–1.02 | 0.097 | 0.87 | 0.76–0.99 | 0.040 |
Post-dilatation balloon maximum diameter (1 mm increase) | 0.86 | 0.43–1.73 | 0.67 |  |  |  |
Post-dilatation balloon maximum inflation pressure (1 mm increase) | 0.94 | 0.84–1.05 | 0.26 |  |  |  |
At the time of PCI | Â | Â | Â | Â | Â | Â |
HbA1c (1% increase) | 1.07 | 0.81–1.42 | 0.65 |  |  |  |
FBS (1 mg/dL increase) | 1.001 | 0.996–1.007 | 0.67 |  |  |  |
CRP (1 mg/dL increase) | 1.16 | 0.84–1.61 | 0.36 |  |  |  |
Total cholesterol (1 mg/dL increase) | 0.996 | 0.987–1.005 | 0.35 |  |  |  |
Triglyceride (1 mg/dL increase) | 1.000 | 0.997–1.003 | 0.85 |  |  |  |
HDL-cholesterol (1 mg/dL increase) | 1.022 | 0.994–1.050 | 0.12 |  |  |  |
LDL-cholesterol (1 mg/dL increase) | 0.989 | 0.978-1.000 | 0.056 | 0.984 | 0.972–0.997 | 0.018 |
At the time of CAS evaluation | Â | Â | Â | Â | Â | Â |
HbA1c (1% increase) | 1.23 | 0.82–1.86 | 0.32 |  |  |  |
FBS (1 mg/dL increase) | 0.999 | 0.992–1.005 | 0.70 |  |  |  |
CRP (1 mg/dL increase) | 0.53 | 0.18–1.55 | 0.53 |  |  |  |
Total cholesterol (1 mg/dL increase) | 0.999 | 0.989–1.009 | 0.81 |  |  |  |
Triglyceride (1 mg/dL increase) | 1.002 | 0.999–1.005 | 0.13 |  |  |  |
HDL-cholesterol (1 mg/dL increase) | 1.001 | 0.982–1.021 | 0.91 |  |  |  |
LDL-cholesterol (1 mg/dL increase) | 0.990 | 0.977–1.004 | 0.17 |  |  |  |